Literature DB >> 15888772

Gastro-oesophageal reflux disease: symptoms, erosions, and Barrett's--what is the interplay?

P Sharma1.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15888772      PMCID： PMC1774529          DOI： 10.1136/gut.2004.052225

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  10 in total

1.  Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study.

Authors:  P Malfertheiner; T Lind; S Willich; M Vieth; D Jaspersen; J Labenz; W Meyer-Sabellek; O Junghard; M Stolte
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 2.  Short segment Barrett's esophagus--the need for standardization of the definition and of endoscopic criteria.

Authors:  P Sharma; T G Morales; R E Sampliner
Journal:  Am J Gastroenterol       Date:  1998-07       Impact factor: 10.864

3.  Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.

Authors:  J E Richter; P J Kahrilas; S J Sontag; T O Kovacs; B Huang; J L Pencyla
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

4.  Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus.

Authors:  R Kim; B B Baggott; S Rose; A O Shar; D L Mallory; S S Lasky; M Kressloff; L Y Faccenda; J C Reynolds
Journal:  Gastroenterology       Date:  1995-02       Impact factor: 22.682

5.  Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.

Authors:  G Holtmann; C Cain; P Malfertheiner
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.

Authors:  Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

7.  Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.

Authors:  P J Kahrilas; G W Falk; D A Johnson; C Schmitt; D W Collins; J Whipple; D D'Amico; B Hamelin; B Joelsson
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

8.  Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed).

Authors:  F Pace; G Bianchi Porro
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

Review 9.  Review article: Helicobacter pylori and reflux disease.

Authors:  P Sharma; N Vakil
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

10.  Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?

Authors:  M Coenraad; A A Masclee; J W Straathof; S Ganesh; G Griffioen; C B Lamers
Journal:  Am J Gastroenterol       Date:  1998-07       Impact factor: 10.864
  10 in total
  1 in total

Review 1.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.